Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis

Table 1

Study characteristics of all included clinical trials (AD and VD).

Study	Publication; year	Patient population	Sample size	Diagnosis criteria	Primary variable	Treatment regimen	Jadad quality score
AD
Shi et al. [37]	2013	Age ≥ 50, MMSE ≤ 26	60	DSM4	MQ, MMSE, HDS-R, ADL	400 𝜇g/day, 12 weeks	3
Rafii et al. [40]	2011	Age ≥ 50,; MMSE (range): 10–24	123	NINCDS/ADRDA	ADAS-Cog, MMSE, NPI, ADCS-ADL	200 𝜇g/day, 16 weeks	5
Zhang et al. [36]	2006	Age (range): 52–78, MMSE (mean ± SD): 15±4	109	DSM3-R	MMSE, ADL	500 𝜇g/day, 24 weeks	3
Yang et al. [35]	2003	Age (range): 65–90,; MMSE ≤ 26	65	DSM4	MMSE, CDR, ADL	300 𝜇g/day, 16 weeks	3
Zhang et al. [39]	2002	Age (range): 50–80,; MMSE (range): 10–26	197	DSM4	ADAS-cog, MMSE, ADL, ADAS-non-Cog, CIBIC plus	400 𝜇g/day, 12 weeks	5
Chai et al. [42]	1998	Age (range): 40–62, MMSE (range): 13–23, ADL > 20,; HDS (range): 10–30,	48	DSM3-R	MQ, MMSE, HDS, ADL	400 𝜇g/day, 8 weeks	4
Xu et al. [38]	1995	Age > 50, MMSE (range): 13–23	103	DSM3-R	MMSE, HDS, ADL, MQ	400 𝜇g/day, 8 weeks	3
Liu et al. [41]	1995	Age (range): 51–92,; MMSE (range): 10–26,	28	DSM3-R	MMSE, HDS, ADL, MQ	200 𝜇g/day, 8 weeks	4
VD
Xu et al. [4]	2012	Age (range): 60–85,; MMSE (range): 12–24	78	DSM4-R NINDS-AIREN	MMSE, CDR, ADL	100 𝜇g/day, 12 weeks	4
Zhou et al. [43]	2004	Age (mean ± SD): 70.25±10.89, MMSE (mean ± SD): 13.4±5.2	14	DSM4	MMSE, ADL	300 𝜇g/day, 24 weeks	3